Recent Updates
Recently added Catalysts
MOLN Positive Sentiment Score: 75/100

Molecular Partners to Hold Conference Call to Discuss Fourth Quarter and Full Year 2022 Results and Present at the 43rd Annual Cowen Health Care Conference

Key Takeaway: Molecular Partners AG will issue a press release summarizing its fourth quarter and full year 2022 results, followed by an investor call. CEO Patrick Amstutz is scheduled to present at the 43rd Annual Cowen Health Care Conference on March 8, 2023. The financial results will be publicly available on March 9, 2023, and the conference call is set for March 10, 2023. The company is engaged in developing DARPin therapeutics and has ongoing partnerships in oncology and infectious disease.

Market Sentiment Analysis

POSITIVE FACTORS

  • Molecular Partners is advancing its new class of protein drugs.
  • The company has established partnerships with leading pharmaceutical firms.
  • The upcoming conference call will provide a key update on financial results.

Full Press Release Details

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will issue a press release summarizing its highlights and financial results for the fourth quarter and full year of 2022, followed by an investor call the following day. Chief Executive Officer Patrick Amstutz will also deliver a company presentation at the 43rd Annual Cowen Health Care Conference in Boston, MA. Please see all details below:
Conference Presentation Details:
Cowen Health Care Conference
March 8, 2023, at 9:10am ET (3:10pm CET)
Full Year 2022 Release Date and Time:
March 9, 2023, 4:00 pm ET (10:00 pm CET)
March 10, 2023, 8:00 am ET (2:00 pm CET)
The full year 2022 results presentation will also be webcast live and will be made available on the Company’s website under the investor section. The replay will be available for 90 days following the presentation.
In order to register for the full year 2022 conference call on March 10, 2pm CET / 8am ET, please dial the following numbers approximately 10 minutes before the start of the presentation:
Switzerland 0800-246787
USA 1-866-652-5200
Full list of dial-in numbers: Linked here
Conference ID Please ask to be joined into the Molecular Partners call.
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of oncology and infectious disease and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com; Find us on Twitter - @MolecularPrtnrs
For further details, please contact:
Tel: +1 781 420 2361
Antonio Ligi, Head of Communications
Zurich-Schlieren, Switzerland
Tel: +41 79 723 36 81

Frequently Asked Questions

When will Molecular Partners release their Q4 2022 results?

The Q4 2022 results will be released on March 9, 2023, at 4:00 pm ET.

What is the date of the Cowen Health Care Conference presentation?

The presentation at the Cowen Health Care Conference is on March 8, 2023.

How can I access the full year 2022 results presentation?

It will be webcast live and available on the Company’s investor section online.

What are DARPin therapeutics?

DARPin therapeutics are custom-built protein drugs aimed at addressing unmet medical needs.

Who can I contact for more information about Molecular Partners?

You can contact Seth Lewis or Antonio Ligi via their provided emails and phone numbers.

Last updated: Mar 2, 2023